Trial Profile
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs ADH 1 (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer; Pancreatic cancer
- Focus Adverse reactions; Biomarker
- 26 Jan 2018 Status changed from recruiting to completed.
- 08 May 2013 Adherex Technologies added a trial company and lead trial centre as reported by ClinicalTrials.gov.
- 10 Apr 2013 New trial record